Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular and clinical characterization of PTPN2 expression from RNA-seq data of 996 brain gliomas.

Journal of neuroinflammation - 15 May 2018

Wang Peng-Fei, Cai Hong-Qing, Zhang Chuan-Bao, Li Yan-Michael, Liu Xiang, Wan Jing-Hai, Jiang Tao, Li Shou-Wei, Yan Chang-Xiang

Abstract excerpt

BACKGROUND: Immune checkpoint inhibitors have been shown to promote antitumor immunity and achieve durable tumor remissions. However, certain tumors are refractory to current immunotherapy. These negative results encouraged us to uncover other therapeutic targets and strategies. PTPN2 (protein tyrosine phosphatase, non-receptor type 2) has been newly identified as an immunotherapy target. Loss of PTPN2 sensitizes...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Area Under Curve
Share to Brain Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Lymphocyte Specific Protein Tyrosine Kinase p56(lck)

Share to Neutrophils

Share to Protein Tyrosine Phosphatase, Non-Receptor Type 2

Share to STAT1 Transcription Factor

Source

Open in PubMed Open full text

Identifiers

PMID: 29764444
DOI: 10.1186/s12974-018-1187-4
PMCID: PMC5953404

Genes

PTPN2
HCK
LCK
STAT1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular and clinical characterization of PTPN2 expression from RNA-seq data of 996 brain gliomas.PMID 29764444Read ↗

Immune checkpoint PTPN2 predicts prognosis and immunotherapy response in human cancersSemantic proximity Read ↗

Single-cell and bulk sequencing analyses reveal the immune suppressive role of PTPN6 in glioblastomaSemantic proximity Read ↗

PTPRN Serves as a Prognostic Biomarker and Correlated with Immune Infiltrates in Low Grade GliomaSemantic proximity Read ↗

Transcriptomic Analysis Identified two Subtypes of Brain Tumor Characterized by Distinct Immune Infiltration and PrognosisSemantic proximity Read ↗

PTPRC as a pan-cancer biomarker: Prognostic significance and immune microenvironment interactionsSemantic proximity Read ↗

Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low-grade gliomaSemantic proximity Read ↗

ANXA2 is correlated with the molecular features and clinical prognosis of glioma, and acts as a potential marker of immunosuppressionSemantic proximity Read ↗

TTF2 as a Potential Biomarker and Immunotherapy Target in Glioma Diagnosis and PrognosisSemantic proximity Read ↗

The pyroptosis-related gene signature predicts prognosis and reveals immune microenvironment infiltration in reclassified glioblastoma based on 2021 WHO classificationSemantic proximity Read ↗

Elevated TYROBP expression predicts poor prognosis and high tumor immune infiltration in patients with low‑grade gliomaSemantic proximity Read ↗

CNPY4 is a potential promising prognostic-related biomarker and correlated with immune infiltrates in gliomas.Semantic proximity Read ↗

BST2 is an immune-related prognostic biomarker for gliomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.